Here are links to more details for all of the American College of Cardiology (ACC) late-breaking trial presentations at the ACC.23 meeting March 4-6, in New Orleans. These key late-breaking science sessions include studies in all aspects of cardiovascular medicine, including interventional cardiology, structural heart, cardiac surgery, electrophysiology and drug therapies. Search all the ACC.23 sessions.
Joint ACC/Journal of the ACC Late-Breaking Clinical Trials
Saturday, March 4, 9:30 – 10:30 a.m. CT. Main Tent (Great Hall)
• CLEAR Outcomes Trial: Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients at High Cardiovascular Risk. Presented by Steven E. Nissen.
• TRILUMINATE Pivotal: A Landmark Randomized Clinical Trial of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation. Presented by Paul Sorajja.
• Statins TO Prevent the Cardiotoxicity From Anthracyclines: The STOP-CA Trial. Presented by Tomas G. Neilan.
Featured Clinical Research I
Saturday, March 4, Noon – 1:15 p.m. CT. Room 257
• HALO Trial: Results From a Phase 2, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients With Uncontrolled Hypertension. Presented by Deepak L. Bhatt.
• Effect of Myocardial Viability, Percutaneous Coronary Intervention and Functional Recovery on Clinical Outcomes in the REVIVED-BCIS2 Randomized Trial. Presented by Divaka Perera.
• AIMI-HF Trial: Ischemia and Viability Imaging in Heart Failure: The Alternative Imaging Modalities in Ischemic Heart Failure Trial. Presented by Lisa Mielniczuk.
• Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: A Multimodality Imaging Study (the Yellow III Study). Presented by Annapoorna Subhash Kini.
• On-site Computed Tomography-derived Fractional Flow Reserve to Guide the Management of Patients With Stable Coronary Artery Disease: The TARGET Randomized Trial. Presented by Yundai Chen.
Joint ACC/New England Journal of Medicine Late-Breaking Clinical Trials
Sunday, March 5, 8 – 9:15 a.m. CT. Main Tent (Great Hall)
• Minimally Invasive Versus Conventional Sternotomy For Mitral Valve Repair Surgery: An Expertise Based Multicentre Randomised Controlled Trial (UK Mini Mitral). Presented by Enoch Akowuah.
• RENOVATE-COMPLEX-PCI: Intravascular Imaging-guided Versus Angiography-guided Procedural Optimization in Complex Percutaneous Coronary Intervention. Presented by Presented by Joo-Yong Hahn.
• Transcatheter Edge-to-edge Repair of Functional Mitral Regurgitation in Heart Failure: Final Five-year Results From the COAPT Trial. Presented by Gregg W. Stone.
• Transcatheter Versus Surgical Aortic Valve Replacement in Aortic Stenosis Patients at Low Surgical Risk: 3-year Outcomes From the Evolut Low Risk Trial. Presented by John K. Forrest.
• BIOVASC: Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndromes and Multivessel Coronary Disease. Presented by Roberto Diletti.
Late-Breaking Clinical Trials III
Sunday, March 5, 9:45 – 11 a.m. CT. Main Tent (Great Hall)
• Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations For Heart Failure (BETTER CARE-HF): A Pragmatic, Cluster-randomized Trial Comparing Two Ambulatory Clinical Decision Support Tools. Presented by Amrita Mukhopadhyay.
• A Nationwide Randomized Trial of Electronically Delivered Nudges to Increase Influenza Vaccination Uptake: The NUDGE-FLU Trial. Presented by Niklas Dyrby Johansen.
• A Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease (PCDS Statin). Presented by Salim S. Virani.
• Translating Polygenic Risk For Coronary Artery Disease Into Clinically Actionable Information Using Causal Artificial Intelligence. Presented by Brian A. Ference.
• ACCESS: A Randomized Trial Assessing the Impact of Eliminating Copayment For High Value Preventive Medications For Low-income Seniors With Cardiovascular-related Chronic Diseases. Presented by Diseases David Campbell.
Featured Clinical Research II
Sunday, March 5, 12:15 – 1:30 p.m. CT. Main Tent (Great Hall)
• RAPID-HF: Atrial Pacing For Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. Presented by Barry Borlaug.
• Association of a Low-carbohydrate High-fat (Ketogenic) Diet With Plasma Lipid Levels and Cardiovascular Risk in a Population-based Cohort. Presented by Iulia Iatan.
• STREAM-2: Pharmaco-invasive Reperfusion Strategy With Half-dose Tenecteplase in Older St-elevation Myocardial Infarction Patients. Presented by Frans J. J. Van de Werf.
• Comparison of 3-month Versus 12-month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-eluting Stents With Ultrathin Struts And Advanced Polymer Technology: The HOST-IDEA Randomized Clinical Trial. Presented by Hyo-Soo Kim.
• Safety and Efficacy of Transcatheter Edge-to-Edge Mitral Repair in Degenerative Mitral Regurgitation: An Analysis Of The STS/ACC TVT Registry. Presented by Raj R. Makkar.
Clinical and Investigative Horizons
Sunday, March 5, 2 – 3:15 p.m. CT. Room 338.
• Prediction of Preeclampsia Using High-Sensitivity Troponin I. Presented by Dirk Westermann.
• Outcomes in High-risk Pulmonary Embolism Patients Undergoing FlowTriever Mechanical Thrombectomy: Results From The FLAME Study. Presented by Mitchell J. Silver.
• Health 360x Registry: Equitable Access to Point of Care Decentralized Clinical Trials. Presented by Elizabeth O. Ofili.
• Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic Val122ile Variant. Presented by Bernhard Haring.
• Impact Of Remote Cardiac Device Monitoring on Green House Emissions: Data From the Global Cardiovascular Carbon Footprint (GCCF) Project. Presented by Dhanunjaya R. Lakkireddy.
Joint ACC/Journal of the American Medical Association Late-Breaking Clinical Trials
Monday, March 6, 8:30 – 9:45 a.m. CT. Main Tent (Great Hall)
• Pulsed Field Ablation Treatment in Paroxysmal and Persistent Atrial Fibrillation Patients: Acute and Long-term Outcomes From the Pulsed AF Pivotal Trial. Presented by Atul Verma.
• Impact of Heart Failure Management Using Thoracic Fluid Monitoring From a Novel Wearable Sensor: Results of the Benefits of Microcor (μCor) in Ambulatory Decompensated Heart Failure (BMAD) Trial. Presented by John P. Boehmer.
• A Novel Breakthrough in Wrist-Worn Transdermal Troponin-I-Sensor Assessment For Acute Myocardial Infarction. Presented by Partho P. Sengupta.
• Efficacy and Safety of Macitentan Tadalafil Fixed Dose Combination in Pulmonary Arterial Hypertension: Results From the Randomized Controlled Phase III A DUE Study. Presented by Kelly Chin.
• Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes (COORDINATE)-Diabetes: Primary Results. Presented by Neha J. Pagidipati.
Late-Breaking Clinical Trials V
Monday, March 6, 11 a.m. – 12:15 p.m. CT. Main Tent (Great Hall)
• Vigorous Exercise in Individuals With Hypertrophic Cardiomyopathy (HCM): Primary Results of the Prospective, Multinational Lifestyle and Exercise in HCM (LIVE-HCM) Study. Presented by Rachel J. Lampert.
• Return-to-Play For Elite Level Athletes With Sudden Cardiac Death Predisposing Genetic Heart Diseases. Presented by Katherine A. Martinez.
• Anticoagulation Strategies in Non-critically Ill Hospitalized COVID-19 Patients: Principal Outcomes of the Freedom COVID Anticoagulation Trial. Presented by Valentin Fuster.
• The STELLAR Phase III Trial: A Study of Sotatercept in Combination With Background Therapy For the Treatment of Pulmonary Arterial Hypertension. Presented by Marius M. Hoeper.
• Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, A Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial. Presented by Christie M. Ballantyne.
Featured Clinical Research III
Monday, March 6, 12:45 – 2 p.m. CT.
• Masters@Heart: Lifelong Endurance Exercise and Its Relationship With Coronary Atherosclerosis. Presented by Ruben De Bosscher.
• Residual Inflammatory Risk in Contemporary Statin Treated Patients: A Collaborative Analyses Of 31,197 Participants in the PROMINENT, REDUCE-IT, and STRENGTH Trials. Presented by Paul M. Ridker.
• The LOADSTAR Trial: Comparison Between Targeted Low-Density Lipoprotein Cholesterol Level Based Versus High-Intensity Statin Therapy in Patients With Coronary Artery Disease. Presented by Myeong-Ki Hong.
• CAMEO-DAPA Trial: Evaluation of the Mechanism of Benefit For Dapagliflozin in Heart Failure With Preserved Ejection Fraction: An Invasive Hemodynamic Randomized Trial. Presented by Barry Borlaug.
• Safety and Efficacy of Virtual Care Team Guided Therapeutic Optimization During Hospitalization in Patients With HFrEF: The IMPLEMENT-HF Study. Presented by Ankeet Bhatt.
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com